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1. Introduction 
The clinical applications of cardiovascular magnetic resonance imaging (CMR), are 
expanding as the result of the development in hardware, pulse sequence and the ability of 
post-processing techniques. As the result of the flexibility of CMR to use different pulse-
sequences, with or without the use of Gadolinium, CMR has developed as a powerful tool 
for clinical relevant tissue characterization. CMR in combination with the contrast-
enhancement (CE) technique was initially developed to distinguish viable from non-viable 
myocardium following myocardial infarction. Nowadays,  CE-CMR  is increasingly used for 
tissue characterization in ischemic as well as  non-ischemic cardiomyopathies to determine 
the exact etiology, guide proper treatment, and predict outcome and prognosis. In this 
chapter, we would like to discuss and illustrate the value of CE-CMR imaging in various 
cardiomyopathies. 
2. Utility of different CMR acquisition modes in cardiomyopathy 
CMR imaging  includes several techniques that can be used in various combinations to 
assess left ventricular functional parameters, morphology, as well as myocardial disorders 
(such as edema, scar/fibrosis, microvascular obstruction, myocardial salvage) within one 
examination. Therefore, it is increasingly used in clinical practice for the diagnosis and 
management of cardiac diseases. In this respect, recent reviews concerning this aspect have 
been published (Marcu et al., 2007; Olimulder et al. 2011; Vogel-Claussen et al. 2006; 
Vohringer 2007; Weinsaft et al. 2007). Some technical aspect of cine - and CE imaging but 
also T2-weighted imaging (increasingly used when CE imaging is applied) are shortly 
discussed below. 
2.1 Cine CMR for quantitative assessment of ventricular dimension, function and 
mass 
By application of ECG-gated, breath-holding, cine-bright blood sequences, a stack of 
contiguous left ventricular short-axis slices (5-10 mm thick) are made from basal to apical 
(figure 1a) (Marcu et al. 2006). CMR is a tomographic technique that uses volumetric 
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
440 
quantification based on Simpson’s rule. Each separate slice is distributed approximately in 
30 phases (simplified in figure 1b; from 1 separate slice, 8 phases from end-diastolic to end-
systolic are shown); the endocardium is traced manually in the end-diastolic and end-
systolic phase. Left ventricular end-diastolic and end-systolic volume is then calculated by 
summation of the endocardial surfaces and multiplication by the slice thickness of each 
separate slice. 
  
 
Fig. 1. Schematic figure for A: multiple short axis slices from basal to apical are made from a 
four chamber view, B: from 1 separate short axis slice, phases from end-diastolic to end-
systolic are illustrated. 
Left ventricular ejection fraction is calculated by the formula: ((end-diastolic volume – end-
systolic volume)/end-diastolic volume) × 100%. 
Left ventricular mass can be calculated by 1. tracing the epicardium in the end-diastolic 
phase in each separate slice;  2. obtaining a myocardial volume by summation of the 
surfaces between the epicardial and endocardial  lines and multiplication by the slice 
thicknesses;  and 3. multiplication of the myocardial volume with weight density (1.05 
g/cm3) of muscle.  
2.2 CE-CMR imaging for assessment of damaged myocardium 
The technique of CE-CMR imaging involves an intravenous injection of a contrast agent 
(e.g., gadolinium at a preferred dose of 0.2 mmol/kg body weight) followed by an ECG-
gated T1-weight pulse sequence 10-15 minutes after injection (5 minutes after injection if 
microvascular obstruction is assessed). (Jackson et al. 2007) The timing of the image 
acquisition is of paramount importance, as too early image acquisition reduces the 
difference in contrast between normal and damaged myocardium (such as scar or 
fibrosis) because of an insufficient washout of contrast medium from the normal 
myocardium; too late image acquisition, on the other hand, may result in an excessive 
washout from damaged myocardial tissue that leads to an inferior signal-to-noise ratio. 
(Vogel-Claussen et al. 2006) The typical pulse sequence for CE-CMR imaging is a 
segmented T1-weighted inversion-recovery-prepared fast gradient-echo sequence. An 
inversion-recovery pulse is used to null the signal of normal myocardium in order to 
optimize the difference between normal and damaged myocardial areas (which still 
contain contrast medium) (Figure 2). 
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Fig. 2. Schematic figure for inversion time (TI) mapping. Following the ECG trigger, an 
inversion recovery (IR) pulse is applied. Before image acquisition, low-resolution TI scout 
images at mid-ventricular level with increasing TI (interval TI 30 msec) are performed. The 
optimal time to inversion (TI0) is defined visually as the inversion time at which the 
uninfarcted myocardium (1) is nulled. (2) = infarcted myocardium. 
The optimal inversion time depends on the contrast clearance from the normal myocardium 
which may show considerable inter-patient variability, depending on several factors such as 
the patient weight, left ventricular or renal function. Therefore, just before image 
acquisition, the inversion time is optimized on a per-patient basis using low-resolution scout 
images at mid-ventricular level with increasing inversion times at intervals of 30ms, from 
which the optimal inversion time can be derived (Jackson et al. 2007). The process is 
synchronized to the R-wave of the ECG and mid-diastolic images are acquired every other 
heart beat during breath-hold (Marcu et al. 2007). 
2.3 T2-weighted CMR imaging for assessment of myocardial edema 
T2-weighted CMR imaging is a pulse sequence sensitive to regional or global increases of 
myocardial water (a substantial feature of inflammatory responses) (Zagrosek et al. 2008; 
bdel-Aty et al. 2005). Therefore very useful in the (sub) acute phase of myocardial infarction 
and myocarditis. The long T2 relaxation times of water-bound protons are used to generate 
a water-specific contrast when applying T2-weighted sequences resulting in a high signal 
intensity of edematous tissue. Standard T2-weighted imaging of myocardial edema typically 
utilizes turbo spin-echo readouts with or without fat saturation pulses (to separate fat from 
water), mostly combined with dark-blood preparation (Eitel et al. 2011). An alternative 
acquisition mode can be the T2-prepared steady state free precession technique, which may 
be more reliable in imaging edema as it provides fewer artifacts and has better diagnostic 
accuracy than conventional darkblood acquisitions (Kellman et al. 2007).  
www.intechopen.com
  
Cardiomyopathies – From Basic Research to Clinical Management 
 
442 
3. CE-CMR findings in the different cardiomyopathies  
3.1 CE-CMR after myocardial infarction 
Myocardial infarction occurs after coronary occlusion of at least 20-30 minutes (without 
sufficient collateral blood supply to the affected myocardium) (Edelman, 2004). In the early 
phase of myocardial infarction, cellular degradation in the infarcted myocardium results in 
an increase in the permeability and enlargement of the extravascular space (edema), and 
thus, an increased distribution volume for the CMR contrast agent. Later on, due to different 
wash-in and wash-out kinetics, myocardial scars retain contrast agents longer than normal 
myocardium. The net result of both mechanisms is that infarcted myocardium appears 
bright on CE-T1-weighted images.  
CE in patients with MI generally shows a typical pattern that is related to the perfusion area 
of the culprit vessel. Myocardial changes (and thus CE) of the subendocardium can 
generally be found which may extend to a transmural distribution in cases with prolonged 
coronary occlusion (Figure 3a,b). 
 
 
Fig. 3. CE-CMR patterns post myocardial infarction. A,B:  CE short axis and long axis view 
showing transmural inferior infarction (black arrow). C,D: Short axis and long axis view 
showing an inferior infarction with microvascular obstruction (white arrow).  
In patients after MI, the assessment of myocardial viability can provide clinically important 
information to guide further treatment because only viable myocardium may benefit from 
revascularization (Kim et al., 2005). Generally, a standardized 17 myocardial segment-model 
is used to report the results of viability assessment by CE-CMR (Figure 4) (Cerquira et al., 
2002). 
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Fig. 4. Bulls eye scheme according to the 17 segmental model, demonstrating CE 
characteristics post myocardial infarction. A: assignment of the 17 segments to one of the 3 
major coronary arteries, with segment 1, 2, 7,8, 13, 14, and 17 corresponding to the left 
anterior descending coronary artery ; segments 3, 4, 9, 10 and 15 corresponding to the right 
coronary artery when it is dominant; and segments 5, 6, 11, 12, and 16 are assigned to the 
left circumflex artery. B: Transmural inferior MI. C: Inferoseptal MI with a core zone (white 
area) and a peri infarction zone (gray area). D: Inferior MI with microvascular obstruction 
(black area in myocardial infarction area). 
In addition, quantification of infarcted tissue helps to prognosticate left ventricular 
remodeling (Orn et al., 2007). In this respect, the transmural extent of infarcted tissue as 
determined by CE-CMR has been shown to be a powerful predictor of the contractile 
response to both medical therapy and myocardial revascularization (Weinsaft et al., 2007). 
Primary coronary intervention with stent implantation is meanwhile the standard for 
treatment of all acute ST-segment elevation myocardial infarctions, even in cases with a very 
challenging anatomy (Basalus et al., 2009). The early intervention rapidly restores the 
patency of the epicardial coronary vessels and often improves the prognosis, as is early 
indicated by ST-segment resolution on the electrocardiogram (van der Zwaan et al., 2010). 
Nowadays, aspiration of thrombi is often performed prior to stent implantation in 
thrombus-containing lesions in order to minimize distal embolization (Hermens et al. 2010;  
Stoel et al., 2009) that contributes to the development of left ventricular dysfunction after MI. 
In our recent CMR study, we also found that left ventricular wall motion abnormalities were 
significantly better in patients who underwent successful early revascularization for acute 
myocardial infarction (Olimulder et al., 2011). 
Increasing interest is also laid on the  assessment of characteristics of infarcted myocardial 
tissue as potential predictor of life-threatening ventricular arrhythmias. Recently, a highly 
significant relation between inferior MI and ventricular arrhythmias has been observed 
(Pascale et al. 2009). Multivariate analysis of data from 91 patients suggested that the 
heterogeneity of infarcted tissue (also called peri infarct zone or border zone), can be an 
important predictor of spontaneous ventricular arrhythmias (Roes et al., 2009). 
The area of CE tends to be larger during the acute phase of MI (first week) and progressively 
decreases in size during the healing phase (1-4 weeks), until it reaches the state of a healed 
myocardial infarction (after 4 weeks) (Thygesen et al. 2007). These observations are consistent 
with the established pathological understanding of remodeling after MI: during the acute 
phase, there is myocardial edema which subsequently regresses while the necrotic 
myocardium is replaced by scar tissue (Marcu et al., 2007). Experimental studies have revealed 
that final MI size is strongly influenced by the extent of the edema in the acute phase, which is 
also called area at risk. By combining T2-weighted images to visualize myocardial edema (and 
thus the area at risk) and CE-CMR imaging to visualize scar (the final infarct size), a myocardial 
salvage index can be calculated by subtracting the infarct size from the area at risk (Aletras et al., 
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2006). The myocardial salvage index has recently shown to be independently associated with 
adverse left ventricular remodeling and early ST-segment resolution, and may represent an 
interesting parameter for the assessment of novel reperfusion strategies in patients with 
myocardial infarction (trial registration number: NL19151.044.07). 
In addition, some patients develop microvascular obstruction within the ischemic 
myocardial region in the acute phase of a myocardial infarction (Masci et al. 2010). 
Microvascular obstruction is represented by a dark zone within the infarcted region, usually 
located in the subendocardium because the contrast medium does not reach this area 
(Figure 3c,d). Its presence is associated with greater left ventricular remodeling and inferior 
clinical outcome. (Nijveldt et al. 2008). 
3.2 CE-CMR in nonischemic cardiomyopathies 
3.2.1 Hypertrophic cardiomyopathy 
Hypertrophic cardiomyopathy is a primary myocardial disease characterized by focal (mostly 
septal) or diffuse left ventricular wall thickening (with or without left ventricular outflow 
obstruction). Myofibrillar hypertrophy and disarray and myocardial fibrosis have been 
described histologically. Inadequate capillary density and intimal hyperplasia of intramural 
coronary arteries, which were also seen in such patients, may contribute to myocardial 
ischemia (Marcu et al., 2007).  There are predilection patterns of CE in patients with 
hypertrophic cardiomyopathies: more than 80% of patients exhibit patchy fibrosis at the right 
ventricular insertion points and in the anteroseptal wall in the region of characteristic septal 
thickening (Figure 5ab; Figure 6a) (Moon et al., 2003; Choudhury et al., 2002). 
 
 
Fig. 5. CE-CMR patterns in nonischemic cardiomyopathies. A,B: CE short axis and long axis 
view showing hypertrophic cardiomyopathy with patchy CE septal and in the right 
ventricular insertion points. (black arrow). C,D: Short axis and long axis view showing 
dilated cardiomyopathy with CE having septal midwall predominance (white arrow). 
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Fig. 6. Bulls eye scheme according to the 17 segmental model, demonstrating typical CE 
patterns in nonischemic cardiomyopathies. A: Hypertrophic cardiomyopathy with 
predilection CE (i.e., fibrosis) pattern at the right ventricular insertion points (I) and 
anteroseptal (II). Myocardial fibrosis is also located in non-hypertrophic segments. B: 
Idiopathic dilated cardiomyopathy with CE predominantly located in the midwall with 
septal predominance. C: Arrhythmogenic right ventricular cardiomyopathy with midwall 
CE found in the basal anterior region. CE is also found in the right ventricular outflow tract. 
Myocardial fibrosis, however, is also located in non-hypertrophic segments (Bohl et al., 
2008). As the amount of CE in hypertrophic cardiomyopathies often corresponds with 
functional parameters and the frequency of cardiac events, CE-CMR may potentially be 
useful for risk stratification and selection for implantable cardioverter defibrillator 
implantation  (Rubinstein et al., 2010). Presence and extent of CE following percutaneous 
alcohol septal ablation for the treatment of significant left ventricular outflow tract 
obstruction indicates the location and extent of therapeutic myocardial tissue destruction. 
(Sievers et al., 2002). 
3.2.2 Idiopathic dilated cardiomyopathy 
Idiopathic dilated cardomyopathy is characterized by dilation and impaired contractility of 
the left ventricle or both ventricles in the absence of abnormal loading conditions (e.g., 
arterial hypertension; valvular disease), and/or a cardiomyopathy with a distinct cause 
(e.g., ischemic heart disease; peripartum cardiomyopathy; toxin, chemotherapy or 
tachycardia induced cardiomyopathy; certain endocrinopathies) (Mueller & Attili, 2008). 
Histology is nonspecific and a variety of myocardial tissue alterations may occur or coexist, 
including myocyte hypertrophy and segmental or diffuse interstitial fibrosis. Current CE-
CMR techniques are unlikely to detect diffuse fibrosis due to limited voxel resolution 
(Vohringer et al., 2006).  Myocardial fibrosis in idiopathic dilated cardiomyopathy is mostly 
seen in the left ventricular midwall with septal predominance and a linear pattern (Figure 
5c,d; Figure 6b); however, it has occasionally been described at subendocardial and 
subepicardial locations with a more patchy pattern. (Bohl et al., 2008).  Of note, in various 
studies the prevalence of myocardial fibrosis varied from 13% to 62% (Yokokawa et al., 2009; 
Isbell et al., 2006).  It has been suggested that the degree of CE may correlate with functional 
impairment of the left ventricle (Koito et al., 1996). There are preliminary data 
demonstrating that the presence of CE is associated with an unfavorable clinical outcome 
and may be a predictor of sudden death in patients with idiopathic dilated cardiomyopathy 
(Yokokawa et al., 2009, 2009; Assomull et al., 2009). 
3.2.3 Arrhythmogenic right ventricular cardiomyopathy 
The arrhythmogenic right ventricular cardiomyopathy is characterized by structural and 
functional abnormalities, with progressive fibrous and fatty infiltration involving variable 
regions of the right and left ventricular myocardium. This process finally leads to 
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progressive right ventricular failure and ventricular tachyarrhythmia (Bohl et al., 2008). 
Diagnosis of this condition remains a challenge, with nonspecific abnormalities on 
echocardiographic and angiographic examinations. Endomyocardial biopsy has a low 
sensitivity, as samples are usually taken from the septum, a region that is infrequently 
involved (Bohl et al., 2008). Further, endomyocardial biopsy is potential a dangerous 
procedure.  
Information from CE-CMR may help to guide targeted endomyocardial biopsies. 
Predilection patterns with midwall CE are found in the basal anterior region (Figure 6c) 
and/or the right ventricular outflow tract. These patterns of fibrosis correlate with fibro-
fatty replacement of the myocardium at histologic assessment and predict induction of 
ventricular tachycardia during electrophysiological studies. As the presence of 
arrhythmogenic right ventricular cardiomyopathy  cannot be ruled out based on CMR 
findings alone, standardized guidelines have been proposed which define major and minor 
criteria, including morphological, histological, electrocardiographic, functional, and genetic 
characteristics (McKenna et al., 1994). 
3.3 CE-CMR in myocarditis 
3.3.1 Myocarditis 
Myocarditis is an acute or chronic inflammatory disease of the myocardium, which can be 
caused by viruses or initiated by post-infectious immune or primarily organ-specific 
autoimmune responses. (Caforio et al., 2002). Patients generally recover or infrequently 
develop dilated cardiomyopathy, sometimes even with life-threatening complications 
including severe heart failure and malignant arrhythmias (Zagrosek et al., 2008). Diagnosis 
of myocarditis is challenging because of a diverse clinical presentation and a limited 
sensitivity of endomyocardial biopsies, but may be facilitated by use of CE-CMR or 
myocardial global relative enhancement CMR (bdel-Aty et al., 2005; Gutberlet et al., 2008). 
Diagnosis of acute myocarditis is more important nowadays because of the therapeutic 
medical options in selected patients. (Corsten et al., 2010). Presence of CE has been reported 
in 44-95% of patients with myocarditis, (Mahrholdt et al., 2004, 2006) indicating areas of 
myocardial damage with a sensitivity of 100% and a specificity of 90% (compared to 
histopathology) (Mahrholdt et al., 2004).  In acute myocarditis, CE is frequently located in 
the lateral wall, originating from the epicardium. The subendocardium is generally not 
involved, with the exception of eosinophilic myocarditis, which frequently involves the 
endomyocardium (Figure 7a). (Bohl et al., 2008; Deb et al., 2008). 
In chronic myocarditis, besides an increased edema on T2-weighted imaging, an increased 
global relative enhancement is a common finding as confirmed  in immunohistological 
analyses. (Gutberlet et al., 2008). CE-CMR identified areas of myocardial damage in 70% of 
patients with biopsy-proven chronic myocarditis and showed a predilection pattern (left 
ventricular midwall and/or subepicardial).  In myocarditis, CE may provide additional 
information that could help to differentiate between viral origins, as in the majority of 
parvovirus B19 patients, CE is found in the lateral free wall, while in patients with human 
herpes virus 6 myocarditis CE frequently involves the interventricular septal midwall 
(Yelgec et al;2007). In addition, we recently studied a limited number of patients with 
chronic fatigue syndrome and concomitant ebstein barr virus or cytomegalovirus 
myocarditis who showed in the presence of CE a certain predilection of the septal region. 
Inflammatory activity on T2-weighted imaging and myocardial fibrosis on CE-CMR may 
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have relevant prognostic implications in acute and chronic myocarditis and may 
ultimatively serve as a tool to triage patients. In addition, cardiac function and regression of 
myocardial changes can be well observed with CMR.   
 
 
Fig. 7. Bulls eye scheme according to the 17 segmental model, demonstrating typical CE 
patterns in myocarditis and cardiac involvement of other diseases.  
A: Myocarditis with CE frequently located in the lateral wall originating from the 
epicardium (I).  CE patterns in myocarditis differ according to viral origin, with parvovirus 
B19 having CE in the lateral free wall (I), HHV6 having CE frequently in the interventricular 
septal midwall (II), and chronic fatigue syndrome myocarditis having CE anteroseptal and 
inferoseptal (III). B: Sarcoidosis with CE midwall or epicardial; however subendocardial or 
transmural CE may be observed. C: Amyloidosis , usually with a global diffuse CE pattern, 
frequently involving the subendocardium. D: Chagas‘ disease with CE epicardial or 
midwall, with a predilection pattern inferolateral. E. Pulmonary hypertension with CE 
involving the right ventricular insertion points and the interventricular septum. F: Muscular 
dystrophy with CE observed in the midwall. G: Chloroquine induced cardiomyopathy with 
hypertrophy and accompanying CE in the basal septum ( I) and the right ventricular 
insertion points (I). 
3.4 CE-CMR in systemic diseases inducing cardiomyopathy 
3.4.1 Sarcoidosis 
Cardiac involvement in sarcoidosis, a multisystem granulomatous disorder of unknown 
etiology, is clinically often asymptomatic (95%) while autopsy revealed cardiac 
manifestation in up to 60% (Patel et al., 2009). Advanced sarcoidosis leads to septal thinning, 
systolic and diastolic dysfunction, and pericardial effusion which can  be detected with 
echocardiography (Jackson et al., 2007).  Early sarcoidosis, however, is more challenging to 
diagnose, and CMR can be very useful in this context. During the acute stage of this disease, 
regions of active inflammation and edema are visible on T2-weighted images as areas of 
increased signal intensity. During the chronic stage, CE will typically appear as a midwall or 
epicardial nonischemic pattern (Figure 7b; figure 8). 
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Fig. 8. CMR in a patient with sarcoidosis. A:  T2 weighted imaging shorta axix view showing 
Figure 8 hyperenhancement epicardial inferior, inferolateral and anterolateral.  
B: Short axis view showing CE epicardial inferior, inferolateral and anterolateral. 
But occasionally subendocardial or transmural CE may be observed, mimicking a pattern of 
post-MI. CE has been found in 50% of all patients diagnosed with sarcoidosis (Shimada et 
al., 2001). CE-CMR may also be useful to evaluate the response to therapy. In a CMR study 
of patients with sarcoidosis, CE was markedly diminished 1 month after the initiation of 
steroid therapy (Shimada et al., 2001).  CE in sarcoidosis patients may be associated with 
future adverse events (including cardiac death) but confirmation in larger patient cohorts is 
required (Patel et al., 2009). 
3.4.2 Amyloidosis 
Both primary and secondary amyloidosis are characterized by extracellular deposition of 
fibrillar proteins (Mueller et al, 2008), which may lead to restrictive cardiomyopathy with an 
initially preserved systolic left ventricular function (Wynne et al., 2005). In cardiac 
amyloidosis, CE is commonly found as a result of the expansion of interstitial space and 
some endomyocardial fibrosis (Maceira et al., 2008),  leading to a usually global and diffuse 
CE pattern (Jackson et al., 2007). Although the subendocardium is commonly involved (as in 
ischemic heart disease), the distribution of CE is not related to a particular coronary 
perfusion area (Figure 7c; figure 9) (Jackson et al., 2007). 
 
 
Fig. 9. CMR in a patient with amyloidosis.  
A,B: four chamber and short axis view showing diffuse subendocardial CE. 
A B 
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3.4.3 Chagas’ disease 
The parasitic protozoan Trypanosoma cruzi causes Chagas’ disaese, which is endemic in the 
Latin American region (Jackson et al., 2007). During chronic disease, the heart is the most 
frequently affected organ, and patients present with refractory heart failure, disorders of the 
conduction system, or ventricular tachycardia (Marcu et al., 2007; Rochitte et al., 2005). The 
fundamental pathological processes include an inflammatory response, cellular damage 
with a broad variation of intensity (minimal alterations up to extensive necrosis), and 
fibrosis (Rochitte et al., 2007).  Early cardiac involvement may be detected by CE-CMR 
before the onset of symptoms (Rochitte et al., 2003). CE is often located epicardial  or in the 
left ventricle midwall with a inferolateral predilection pattern (Figure 7d), but other regions 
- including the apex - may also sometimes be affected (Jackson et al., 2007).  
3.4.4 Pulmonary hypertension  
Pulmonary arterial hypertension, both primary and secondary, is characterized by an 
increased pulmonary vascular resistance that results in pressure overload on the right 
ventricle (Kovacs et al., 2008). Cine CMR permits accurate assessment of right ventricular 
mass and volumes which is often difficult to accomplish with other imaging modalities 
(Marcu et al., 2007). Myocardial CE is frequently observed in patients with severe 
symptomatic pulmonary artery hypertension with predilection patterns involving both right 
ventricular septal insertion points and the interventricular septum (Figure 7e). CE in the 
interventricular septum was found to be associated with septal bowing (on cine CMR), and 
the extent of CE correlated inversely with right ventricular systolic function (Blyth et al., 
2005). 
3.4.5 Muscular dystrophy 
Both Becker and Duchenne muscular dystrophies are progressive X chromosome-linked 
recessive neuromuscular diseases with myocardial involvement in up to 72% of patients 
showing a mildly reduced left ventricular function up to severe left ventricular impairment 
and dilated cardiomyopathy. Cardiac myocyte dystrophin deficiency leads to necrosis 
causing replacement of damaged myocardium by connective tissue and fat in both 
ventricles. On CE-CMR, hyperenhancement is predominantly seen in left ventricular 
midwall (Figure 7f) and has been described in 73-100% of patients (Yilmaz et al., 2008). Early 
diagnosis of myocardial involvement as assessed with CE-CMR may permit an earlier 
treatment of heart failure which could increase life expectancy. 
3.4.6 Chloroquine-induced cardiomyopathy  
Chloroquine-induced cardiomyopathy is a rare iatrogenic disease that is associated with 
long-term intake of chloroquine, which is most frequently prescribed  for treatment of 
rheumatoid arthritis and malaria prophylaxis (Reffelman et al., 2006). This cardiomyopathy 
is characterized by ineffective lysosomal metabolism because of an increase in pH that leads 
to accumulation of lysosomal glycosphingolipids and finally thickening of cardiac walls 
(Pieroni et al., 2007). The time interval between the start of chloroquine therapy and disease 
manifestation varies greatly, ranging from several months to more than 20 years (Reffelman 
et al., 2006). CMR may demonstrate the presence of left ventricular hypertrophy with 
accompanying areas of CE in the basal septum and at the insertion point of the right 
ventricle (Figure 7g).  
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Fabry disease, an X chromosome-linked lysosomal storage disease caused by a deficient 
activity of the enzyme -galactosidase A, can also result in the accumulation of 
glycosphingolipids in multiple organs, including the heart (Pieroni et al., 2007; Gange et 
al.,2009). Fabry disease cardiomypathy should therefore always be considered in the 
differential diagnosis of “idiopathic” left ventricular hypertrophy (in the absence of arterial 
hypertension or valvular disease). 
3.5 CE-CMR in other diseases inducing cardiomyopathy 
3.5.1 Tsako Tsubo cardiomyopathy 
This  relatively ‘novel’ cardiomyopathy is characterized by acute but rapidly reversible 
distinctive regional left ventricular dysfunction, in the absence of significant coronary 
artery disease.  Japanese investigators were intrigued by the unusual end-systolic shape of 
the left ventricle, resembling the original Japanese octupus trap (figure 10a) (Sharkey et 
al., 2011). 
 
 
Fig. 10. CMR of a patient with tsako tsubo. A: cine four chamber view with characteristic 
end-systolic apical ballooning. B,C: four chamber and short axis view with no presence of 
CE in the myocardium. 
Consequently, the term tsako tsubo cardiomyopathy was introduced in 1990. Several 
pathofysiological mechanisms have been proposed, including multivessel coronary spasm, 
catecholamine induced myocardial stunning, coronary emboli with spontaneous 
fibrinolysis, and myocardial inflammation (Eitel et al., 2010). Recently, variant forms are 
described, including inverted tako-tsubo and mid-ventricular ballooning cardiomyopathy 
(Marti et al., 2009; Yasu et al., 2006). 
In the setting of tako tsubo cardiomyopathy, CMR may identify increased myocardial mass 
and myocardial edema (using T2-weighted imaging) as well as the normalization of these 
parameters as the left ventricular dysfunction improves. (Stensaeth et al. 2011). Of important 
note, (with only a few exceptions,  reported in literature) (Koeth et al. 2008) no CE is present 
in this disease, consistent with preserved myocardial viability, as reflected by the transient 
nature of left ventricular dysfunction (figure10b) (Eitel et al, 2010; Deetjen et al., 2006) .At 
follow up, there is complete normalization of left ventricular function, in the absence of CE, 
edema and pericardial effusion (Eitel et al., 2010; Koeth et al., 2008). The lack of CE (initial 
and follow up) allows thus for distinction between different causative aetiologies including 
MI, infiltrative diseases and cases of myocarditis.  
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Therefore, CMR in combination with T2 weighted imaging and CE may provide valuable 
additional information for the differential diagnoses and therapeutic decision-making in 
patients with suspected tako tsubo cardiomyopathy. 
3.5.2 Noncompaction cardiomyopathy 
Left ventricular noncompaction cardiomyopathy is characterized by a thin, compacted 
epicardial layer and a  thick endocardial layer with prominent trabeculation and deep 
recessesm (figure 11) (Jacuier et al,).  
 
 
Fig. 11. Patient with noncompaction cardiomyopathy. A,B: end-systolic and end-diastolic 
four chamber view with characteristic prominent trabeculation and deep recessesm. C,D: 
four chamber and short axis view with no presence of CE. 
It can occur isolated or in association with numerous congenital cardiac malformations, 
including atrial and ventricular septal defects, aortic stenosis, and aortic calcification. It is 
usually diagnosed in pediatric age. Accurate diagnostic criteria are clinically important as it 
is associated with severe left ventricular dysfunction, thrombo-embolism, and ventricular 
arrhythmia. According to Jacuier et al., a CMR-assessed trabeculated left ventricular mass 
above 20% of the global left ventricular mass is highly sensitive and specific for the 
diagnosis of left ventricular noncompaction. Right ventricular noncompaction which can be 
easily assessed with CMR, is reported in up to 60% op patients (Dursun et al., 2010). 
Recently, Dursun et al. found that presence of CE (fibrosis) was found in 70% of the 
investigated patients with left ventricular noncompaction. Dodd et al, showed that the 
amount of CE in patients with left ventricular noncompaction is inversely related with left 
ventricular ejection fraction (Dodd et al., 2007). The presence of CE  is thus probably of bad 
prognosis in this disease (Jacquier et al., 2010).  
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3.5.3 CE-CMR imaging in chemotherapy induced cardiomyopathy 
Several chemotherapeutic therapies in the setting of malignant diseases have been associated 
with the development of cardiac failure.  Chemotherapies with a high incidence of cardiac 
failure are anthracyclines (doxorubicin) 3-26%, and monoclonal antibodies (trastuzumab) 2-
28% (Yeh et al., 2009). The cumulative dose (especially doxorubicin; cumulative dose 550 
mg/m2), the administration schedule, concomitant use of other cardiotoxic therapies, and a 
history of cardiovascular disease, determines the likelihood of inducing cardiomyopathy.  
Little is known about the utility of CE-CMR in the assessment of chemotherapy induced 
cardiomyopathy. Fallah-Rad et al. reported in 10 out of 160 breast cancer patients with 
trastuzumab induced cardiomyopahty (left ventricular ejection fraction < 40%), presence of 
epicardial CE. Recently, Kirthy et al. studied (using CE-CMR) 12 breast cancer patients with 
adjuvant trastuzumab; whereas left ventricular dysfunction was observed, no evidence of 
necrosis or fibrosis was found in any of the patients (Kirthy et al., 2011). Data on other 
chemotherapy induced cardiomypathy assessed with CE-CMR are scarce (Lightfoot et al., 
2010; Wassmuth et al., 2001; Wu et al., 2009). Therefore, further studies are needed to 
validate the usefulness of CE-CMR as a marker for (irreversible) left ventricular dysfunction 
and development as well as prevention of cardiac failure when chemotherapy is given. 
4. Guided endomyocardial biopsy 
CE patterns on CMR imaging may also help to guide endomyocardial biopsies as 
scar/fibrosis patterns on CE-CMR may serve as a map for the exact location to accomplish 
endomyocardial biopsies if necessary; thus enhancing the diagnostic accuracy. A small 
study has indeed confirmed  that the diagnostic performance of  endomyocardial biopsies is 
increased when biopsies are obtained from the region of CE in the case of myocarditis 
(Mahrholdt et al., 2004, 2006). However, according to Yilmaz et al. who where unable to 
confirm the value of CE-CMR for guiding endomyocardial biopsies,  endomyocardial 
biopsies exactly obtained from the region of CE may sometimes be impracticle as the area of 
CE may be small and as a consequence cannot exactly be reached by the bioptome because 
of the limited steerability of the bioptome (Yilmaz et al., 2010). 
5. Screening for cardiomyopathy  
Cardiomyopathy can occur as part of inherited syndromes. In the case of hypertrophic 
cardiomyopathy, over 900 gene mutations have been linked. The gene mutations 
predominantly encode for contractile proteins, such as cardiac myosin-binding protein C 
(MYBPC3) and beta-myosin heavy chain (MYH7) (thick filament of the sarcomere), and 
troponin T and troponin I (encoding for thin filament of the sarcomere; accounting for ≈ 6% 
of the hypertrophic cardiomyopathy-causing mutations). Next to sarcomeric mutations, 
several metabolic disorders are linked to the hypertrophic cardiomyopathy phenotype, such 
as Fabry disease (as mentioned above), an X chromosome-linked lysosomal storage disease 
(Brouwer et al., 2011). Thus, there is currently no consensus of a definitive screening test 
based on genetic studies for hypertrophic cardiomyopathy. Additionally, genetic screening 
can not differentiate between gene carriers who express the disease and those who do not 
(Devlin et al., 2000). As a consequence, the heterogeneous expression includes patients 
suffering from severe symptomatic hypertrophic cardiomyopathy (diminished left 
ventricular function and fibrosis of the myocardium) as well as asymptomatic individuals. 
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CE-CMR imaging is able to provide accurate assessment of functional parameters and 
myocardial disorders in one single examination. Therefore, familial screening (especially in 
autosomal dominant disorders) with CE-CMR may be of utmost importance as  individual 
findings may have significant therapeutic consequences.  
As an example, in our tertiary centre, an 18 year old female patient was diagnosed with 
familiar hypertrophic cardiomyopathy (cardiac myosin-binding protein C). CE-CMR 
imaging revealed assymmetrical septal hypertrophy (septal thickness 38 mm) and presence 
of fibrosis (figure 12).  
 
 
Fig. 12. Screening a relative for cardiomyopathy A. 18 year old female patient with genetic 
disorder cardiac myosin-binding protein C. Short axis view showing assymetrical septal 
hypertrophy with CE anteroseptal. B.  56 year old male patient (father) with the same 
genetic disorder. Short axis view showing identical CE anteroseptal. 
Following the guidelines (septal thickness >30 mm) in addition with a medical history of a 
collapse, she was selected for implantable cardioverter defibrillator therapy (Maron et al., 
2003). Her father, (familiar screened and having the same genetic disorder) showed the same 
pattern of assymetrical septal hypertrophy (septal thickness 24 mm) and presence of fibrosis 
with CE-CMR imaging, following the guidelines not an indication for implantable 
cardioverter defibrillator therapy. As mentioned earlier, the amount of CE in hypertrophic 
cardiomyopathies often corresponds with functional parameters and the frequency of 
cardiac events, therefore CE-CMR may potentially be useful for risk stratification and 
selection for implantable cardioverter defibrillator implantation. 
6. Future developments 
Several new strategies for the treatment of the various forms of cardiomypathy are currently 
subject of research, including the transplantation of primitive cell types (e.g., stem cells or 
myoblasts) into damaged myocardium in an attempt to promote trans-differentiation into 
functional myocardial cells. CE-CMR imaging can be used to monitor such studies and to 
evaluate the results of novel therapeutic strategies such as direct injection of primitive cell 
types into segments with transmural infarction. (Orlic et al., 2002). In animal models, 
mesenchymal stem cells have been labeled with iron-based contrast agents to examine the 
process of “homing” of such cells in the myocardium (Hill et al., 2003; Kraitchman et al., 
2003; Garot et al., 2003). 
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Recently, 3.0 T CMR imaging with a 3D inversion-recovery gradient-echo sequence was 
compared to standard 2D imaging. The 3D technique showed superior spatial image 
resolution, shorter image acquisition time, preserved contrast-to-noise ratio, and similar 
intra and interobserver variabilities (compared to the 2D approach), which could improve 
the clinical utility of CE-CMR in the future (Bauner et al., 2009). At higher heart rates, 
though, motion artifacts can be seen. 
7. Conclusion 
CE-CMR is increasingly used to establish the etiology, monitor therapeutic strategies (follow 
up), and obtain prognostic information in a variety of cardiomyopathies. While CE-CMR 
can provide valuable information, there is considerable overlap in CE patterns. For that 
reason, CE-CMR findings should always be considered in the light of the clinical history and 
presentation as well as findings obtained from other diagnostic modalities. Development in 
CMR hardware and software are required for the ability to perform tissue characterization 
which fully corresponds with histopathological findings. 
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